Table 1.
Characteristics | N | % |
---|---|---|
T stage | ||
T1c | 2 | 6.1 |
T2a | 10 | 30.3 |
T2b | 9 | 27.3 |
T2c | 8 | 24.2 |
T3a | 3 | 9.1 |
T3b | 1 | 3 |
Gleason Score | ||
3 + 3 | 3 | 9.1 |
3+4 | 17 | 51.5 |
4+3 | 5 | 15.2 |
4+4 | 4 | 12.1 |
3+5 | 1 | 3 |
4+5 | 3 | 9.1 |
Low risk (GS < 6 and PSA < 10 and T1c/T2a) | 1 | 3 |
Intermediaterisk(GS = 7 or PSA > 10 or ≤cT2a) | 14 | 42.4 |
High risk (GS ≥ 8 or ≥cT2c or PSA > 20) | 18 | 54.6 |
Hormonal therapy | ||
Yes | 1 | 3 |
No | 32 | 97 |
Radiotherapy delivery | ||
CyberKnife | 27 | 81.8 |
Tomotherapy | 3 | 9.1 |
Synergy | 3 | 9.1 |